Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
复制标题
DOI：
10.2174/187221411794351879
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Rabi, Doreen
中科院分区：
文献类型：
--
作者：
Ho, Josephine;Leung, Alexander K. C.;Rabi, Doreen
由于相关的微血管和大血管并发症，2型糖尿病的患病率正在增加，并造成巨大的卫生保健负担。2型糖尿病的诊断依据是高血糖的临床表现和实验室确认的血糖升高。最初的治疗包括饮食和运动，然后使用口服降糖药和可能的皮下注射胰岛素。在目前可用的口服降糖药中，二甲双胍是一线选择。最近，新的辅助疗法已经被引入，可以改善血糖控制，尽管就糖尿病并发症而言，改变疾病结果的长期效果仍有待观察。对目前非胰岛素治疗的作用机制进行综述。这篇综述文章还将讨论与该领域相关的最新专利。
Type 2 diabetes is increasing in prevalence and causes a significant health care burden due to associated microvascular and macrovascular complications. Type 2 diabetes is diagnosed by clinical findings of hyperglycemia and laboratory confirmation of elevated plasma glucose. Initial therapy includes diet and exercise, followed by the use of oral hypoglycemic agents and potentially subcutaneous insulin injections. Of the oral hypoglycemic agents currently available, metformin is the first-line choice. Recently, new adjunct therapies have been introduced that can improve glycemic control, although the long term effects on modifying the disease outcome in terms of diabetes complications remain to be seen. A review of the mechanism of action of current, non-insulin therapies will be presented. This review article will also discuss recent patents related to the field.